Search Results
Your search for ,gET matches 2979 pages
Showing 751 - 800Recent Studies Explore Efficacy of COVID-19 Vaccination in Patients With Leukemia and Myeloma
Two new studies published in the journal Blood suggest that the BNT162b2 mRNA COVID-19 vaccine may have reduced efficacy in individuals with chronic lymphocytic leukemia (CLL) and multiple myeloma. According to researchers, these studies could help inform the ideal time for vaccination of these...
Squamous Cell Carcinoma of the Head and Neck: Current Status and Future Directions
Although head and neck cancers include multiple histologies and primary sites, squamous cell carcinomas (SCC) originating in the oropharynx, oral cavity, larynx, or hypopharynx are the most common. Today, we recognize different types of head and neck cancers, primarily those that are human...
Estimated Shifts in Cancer Incidence and Death Over Next 2 Decades
In the next 2 decades, rankings of incidence and death across cancer types in the United States will undergo important changes, according to new research published by Lola Rahib, PhD, and colleagues in JAMA Network Open. The study estimates that pancreatic cancer is on course to become the...
Knuckles
The swastikas on his knuckles kept stealing my attention. I tried not to stare but every time he gestured to emphasize his words my gaze snapped back there. That awful symbol, multiplied across all 10 digits, refused to be ignored. The blue lines were blurred and misshapen, probably jail tats. I...
I’m Living the Life I Was Destined to Have
At 33, I’m not living the life I had imagined for myself. If cancer hadn’t interrupted my plans, I would be serving in the United States Army Special Forces by now, a profession that was inspired by my father’s career as a military officer and helicopter pilot and one that I had dreamed about since ...
An Oncologist and His Wife Share a Personal Cancer Story
Gastrointestinal oncologist John Marshall, MD, is well known for his candid observations about cancer treatment and research. In 2006, all the scientific intricacies and sociopolitical dramas of oncology coalesced in Dr. Marshall’s life when his 43-year-old wife, Liza, was diagnosed with breast...
Diet and Exercise Intervention May Increase Efficacy of Chemotherapy in Pediatric Patients With Leukemia
Research published by Orgel et al in the journal Blood Advances showed that restricting calories, reducing fat and sugar intake, and increasing physical activity may boost the effectiveness of chemotherapy for older children and adolescents with leukemia. This intervention, which improved...
President Biden Issues Proclamation on National Cancer Control Month 2021
On March 31, President Joseph R. Biden, Jr, issued the following statement on National Cancer Control Month. Despite the incredible advancements we have made in recent years, cancer remains the second-leading cause of death in the United States. Behind this statistic are millions of Americans who...
Targeting FGFR2b With Bemarituzumab Plus Chemotherapy in Gastric or Gastroesophageal Junction Cancer
Gastric cancer appears to have a new druggable target: fibroblast growth factor receptor 2b (FGFR2b). Targeting FGFR2b with bemarituzumab plus chemotherapy led to clinically meaningful and statistically significant improvements in progression-free survival, overall survival, and response rate in...
An Integrated Framework for Improving Outcomes in Pancreatic Cancer
Drawing on several lines of ongoing research, David A. Tuveson, MD, PhD, has created a theoretical framework to consider while developing clinical trials in pancreatic cancer. In his keynote lecture at the 2020 American Association for Cancer Research (AACR) Special Conference on Pancreatic Cancer, ...
In Cholangiocarcinoma, Does Chemotherapy Response Vary According to FGFR2 Status?
With inhibitors of fibroblast growth factor receptor 2 (FGFR2) fusion and other genetic alterations now in clinical trials for cholangiocarcinoma, there is interest in better understanding what FGFR2 genetic alterations mean for patients. In particular, little is known about the effects of FGFR2...
ClarIDHy Trial: IDH1 Inhibitor Ivosidenib Improves Survival in Cholangiocarcinoma
Ivosidenib, an inhibitor of isocitrate dehydrogenase 1 (IDH1), improved overall survival by almost 3 months in previously treated patients with advanced IDH1-mutated cholangiocarcinoma, compared with placebo, researchers of the global phase III ClarIDHy trial reported at the 2021 Gastrointestinal...
ASCO Names Advance of the Year: Molecular Profiling Drives Progress in Gastrointestinal Cancers
Molecular profiling allows clinicians to identify the molecular and genetic signatures that help to deliver treatments that are highly specific to a tumor. This tool has made possible a number of advances in the past year that are improving care for patients with gastrointestinal cancers. In...
Solving the Mystery of Why Colorectal Cancer Is on the Rise in Young Adults
Excluding skin cancer, colorectal cancer is the third most prevalent and lethal cancer among both men and women in the United States.1 Although the risk of developing colorectal cancer increases with age—more than 90% of cases occur in people aged 50 or older2—recent research shows that the...
Some Patients With Lung Cancer Report Feeling Uninformed About Their Disease, Uninvolved With Their Treatment
More than 1 in 10 patients with lung cancer do not know what type of tumor they have, according to data from a 17-country study carried out by the Global Lung Cancer Coalition (GLCC) presented by Beattie et al at the European Lung Cancer Virtual Congress 2021 (Abstract 209P_PR). Nearly one in five...
Treating Colorectal Cancer in the Time of COVID-19
The treatment of colorectal cancer has always been something of an art—but never more so than during the COVID-19 pandemic. In the spring of 2020, The ASCO Post asked three experts in this malignancy to share their concerns and their approaches to achieving good patient outcomes while minimizing...
Eleven Oncology Practices Receive Quality Certification From the Association for Clinical Oncology
The Association for Clinical Oncology congratulates the 11 practices that prioritized the quality of care they provide by achieving the Quality Oncology Practice Initiative (QOPI®) Certification in the second half of 2020. These practices have shown that they are committed to providing the...
Health-Care Policy Expert Sybil R. Green, JD, RPh, MHA, Brings Wealth of Experience as ASCO’s First Diversity and Inclusion Officer
Sybil R. Green, JD, RPh, MHA, has been named Diversity and Inclusion Officer by ASCO. A health-care policy expert with experience in both corporate and nonprofit organizations, Ms. Green will guide ASCO’s internal and external initiatives aimed at achieving the Society’s equity, diversity, and...
Physician-Patient Relationship: Sacred and Sacrosanct
There are many relationships we build at work in our entire lifetime. Some are good, a few are not, and many are somewhere in between. But of all the relationships we are fortunate enough to build, there is no relationship more valuable and gratifying than the one between a physician and a ...
New Survey Reveals Hesitancy Around COVID-19 Vaccination Among Patients With Hematologic Malignancies and Survivors
A survey of more than 6,500 U.S. patients with blood cancer and survivors revealed that only half are very likely to get a COVID-19 vaccine, while one in three is either unlikely or unsure about it. The nationwide survey was a collaboration between The Leukemia & Lymphoma Society (LLS), Boston...
In Cholangiocarcinoma, Does Chemotherapy Response Vary According to FGFR2 Status?
With inhibitors of fibroblast growth factor receptor 2 (FGFR2) fusion and other genetic alterations now in clinical trials for cholangiocarcinoma, there is interest in better understanding what FGFR2 genetic alterations mean for patients. In particular, little is known about the effects of FGFR2...
Kratom
The ASCO Post’s Integrative Oncology series is intended to facilitate the availability of evidence-based information on integrative and complementary therapies sometimes used by patients with cancer. In this installment, Yen Nien Hou, PharmD, DipIOM, LAc, and Jyothirmai Gubili, MS, focus on...
ASCO’s Road to Recovery Report Outlines Lessons Learned From the COVID-19 Pandemic to Improve Oncology Care
In 2020, ASCO established the Steering Group on Cancer Care Delivery and Research in a Post-Pandemic Environment to evaluate the changes made in oncology care delivery, clinical research, and regulatory oversight in response to the COVID-19 pandemic as well as to make recommendations on how to...
CLEAR Trial: Is Lenvatinib Plus Pembrolizumab the Best First-Line Immunotherapy Doublet in Metastatic Renal Cell Carcinoma?
At the 2021 Genitourinary Cancers Symposium, Motzer et al presented the clinical results of the CLEAR trial, adding a novel regimen, lenvatinib plus pembrolizu-mab, to the growing armamentarium of first-line treatments for patients with metastatic clear cell renal cell carcinoma (RCC). The...
New Report Reviews Methods for Reducing Waste, Improving Efficiency With Expensive Injectable Medications
Every year, significant amounts of drugs left over and unused from single-dose vials are discarded, but because of the way drugs are priced and paid for in the United States, the cost of the discarded amount cannot be recouped, according to a new congressionally mandated report from the National...
ASCO Names Advance of the Year: Molecular Profiling Drives Progress in Gastrointestinal Cancers
Molecular profiling allows clinicians to identify the molecular and genetic signatures that help to deliver treatments that are highly specific to a tumor. This tool has made possible a number of advances in the past year that are improving care for patients with gastrointestinal cancers. In...
In Case You Missed It: Brief Highlights From ASH 2020
In case you missed these while attending the 2020 American Society of Hematology (ASH) Annual Meeting & Exposition, below is a sampler of highlights that were not included in our first round of meeting coverage. Many of these reports are on early-phase clinical trials of agents that may raise...
Professor Gordon McVie, International Cancer Researcher and Patient Advocate, Dies at 76
An imposing painting of sailing ships graced the wall behind the desk in the office of Professor Gordon McVie, BSc (Hons), MBChB, MD, FRCP, FRCPEd, FRCPS (Glas), FMedSci, DSc. It was a gift from one of his patients with cancer, a long-term survivor who said the painting reminded her of him, walking ...
Conversations With the Pioneers of Oncology: Emil J Freireich, MD, FASCO
To hear an interview with Dr. Freireich by Daniel F. Hayes, MD, FASCO, of the University of Michigan Rogel Cancer Center and Past President of ASCO, visit the Journal of Clinical Oncology’s podcast, Cancer Stories, wherever you get your podcasts. In this episode, the Cancer Stories podcast reflects ...
Oncology Community Mourns the Death of Chemotherapy Pioneer Emil J Freireich, MD, FASCO
Legendary oncologist Emil J Freireich, MD, FASCO, died from COVID-19 on February 1, 2021, at The University of Texas MD Anderson Cancer Center in Houston, where he had worked for 50 years. He was 93. During a career that spanned more than 6 decades, Dr. Freireich was relentless in pursuing cures...
How the COVID-19 Pandemic Can Help Improve Cancer Research
The ripple effects of the coronavirus pandemic have been felt in every area of health care. In our medical specialty, oncology, clinical trials of new treatments were upended by COVID-19. In the early months of the pandemic, widespread interruptions in trial enrollment prevented some patients...
United States Surpasses 500,000 Deaths Due to COVID-19
On February 22, President Joseph R. Biden issued remarks to proclaim that over 500,000 Americans have now died from COVID-19 infection. He and Vice President Kamala Harris held a moment of silence and ordered flags be lowered to half-mast at federal buildings for the next 5 days to honor those who...
Chemotherapy Plus Blinatumomab for Philadelphia Chromosome–Negative B-Cell ALL
Results from a phase II study presented by Nicholas J. Short, MD, and colleagues at the 2020 American Society of Hematology (ASH) Annual Meeting & Exposition showed that first-line treatment with a regimen of chemotherapy combined with the monoclonal antibody blinatumomab resulted in increased...
Study Finds Asciminib Safer, More Effective Than Bosutinib in Chronic-Phase CML
Since the introduction of imatinib almost 18 years ago, similar next-generation tyrosine kinase inhibitors have been approved for chronic myeloid leukemia (CML), including dasatinib, nilotinib, bosutinib, and ponatinib. These drugs attack a similar target, making it more likely that resistance to...
New Report Says Cancer and Its Therapies May Impair Survivors' Ability to Work
Although cancer survivors are living longer, cancer and its treatment can result in long-lasting or late-onset impairments that may affect their ability to work, according to a new report from the National Academies of Sciences, Engineering, and Medicine entitled Diagnosing and Treating Adult...
Chinese Society of Clinical Oncology and ASCO Approve First Joint Guideline for Treatment of Stage II to IVA Nasopharyngeal Carcinoma
The Chinese Society of Clinical Oncology (CSCO) and ASCO have approved a joint guideline for the treatment of stage II to IVA nasopharyngeal carcinoma.1 The guideline was drafted by a panel of Chinese and U.S. experts and provides, for the first time, a clear set of recommendations for the use of...
Trading One Disease for Another: Patients With Chronic Graft-vs-Host Disease May Face Lifelong Complications
The field of allogeneic stem cell transplantation continues to improve survival for patients with previously incurable blood cancers. However, up to 50% of patients who undergo transplantation with donor cells will develop chronic graft-vs-host disease, a potentially deadly condition that can also...
Expert Point of View: William Gradishar, MD
William Gradishar, MD, the Betsy Bramsen Professor of Breast Oncology at Northwestern University Feinberg School of Medicine and Deputy Director for the Clinical Network of the Lurie Cancer Center, commented on the findings of the ASCENT biomarker analysis in the closing panel discussion. The...
Study Examines Pregnancy Outcomes in Breast Cancer Survivors
Breast cancer survivors of child-bearing age appear to have a more difficult time becoming pregnant than the general population, and when they do become pregnant, they have a higher risk of preterm labor and need for cesarean section. Fortunately, most women deliver healthy babies, but they are...
Expert Point of View: John C. Krauss, MD
The invited discussant of the GARNET study, John C. Krauss, MD, Medical Oncology Director of the Multidisciplinary Colorectal Cancer Clinic, Rogel Cancer Center of the University of Michigan, Ann Arbor, observed that “impressive” response rates to dostarlimab were demonstrated in a “relatively...
ClarIDHy Trial: IDH1 Inhibitor Ivosidenib Benefits Survival in Cholangiocarcinoma
Ivosidenib, an inhibitor of isocitrate dehydrogenase 1 (IDH1), improved overall survival by almost 3 months in previously treated patients with advanced IDH1-mutated cholangiocarcinoma, compared with placebo, researchers of the global phase III ClarIDHy trial reported at the 2021 Gastrointestinal...
I Credit Cancer Research With Saving My Life
In December 2015, I thought I was through with cancer. I was diagnosed with prostate cancer in 2011 after a routine blood test showed that my prostate-specific antigen (PSA) level was high. I underwent prostatectomy, and although it was clear the cancer had breached the capsule of the prostate, for ...
Looking Back on the 40-Year Career of Richard L. Schilsky, MD, FACP, FSCT, FASCO
The medical career of Richard L. Schilsky, MD, FACP, FSCT, FASCO, spans more than 4 decades and includes a roster of nearly unprecedented accomplishments in patient care, research, and mentoring. He has held leadership positions in academia, first at the University of Chicago, where he spent the...
Delay in Time Between Abnormal At-Home Screening and Colonoscopy May Increase Colorectal Cancer Risk
At-home tests, which measure blood in stool as a potential marker for colon cancer, are often used for colorectal cancer screening. Usage of these tests has increased during the COVID-19 pandemic as patients try to avoid clinical visits. However, effectiveness of these screening tools, along with...
FDA Update: Advisory Committee Meeting to Discuss COVID-19 Vaccine Candidate, Statement on Product Development to Address Virus Variants
On February 4, the U.S. Food and Drug Administration (FDA) announced the scheduling of a meeting of its Vaccines and Related Biological Products Advisory Committee to discuss the request for emergency use authorization for a COVID-19 vaccine from Janssen Biotech Inc. Additionally, Acting...
Impact of COVID-19 on Cancer Care Has Been ‘Profound,’ According to WHO
More than a year since the new coronavirus crisis began, its impact on cancer care has been stark, with “50% of governments (having) cancer services partially or completely disrupted because of the pandemic,” said André Ilbawi, MD, of the World Health Organization’s (WHO) Department of...
ASCO Names Advance of the Year: Molecular Profiling Drives Progress in Gastrointestinal Cancers
Molecular profiling allows clinicians to identify the molecular and genetic signatures that help to deliver treatments that are highly specific to a tumor. This tool has made possible a number of advances in the past year that are improving care for patients with gastrointestinal cancers. In...
Patients in Cancer Remission Also at Higher Risk for Severe COVID-19 Illness
Patients with inactive cancer who are not currently undergoing treatment also face a significantly higher risk of severe illness from COVID-19, according to a new study published by Sun et al in JNCI Cancer Spectrum. The findings underscore the importance of COVID-19 mitigation, like social...
Study Identifies Four Unique Subtypes of Small Cell Lung Cancer
Researchers have developed the first comprehensive framework to classify small cell lung cancer (SCLC) into four unique subtypes based on gene expression and have identified potential therapeutic targets for each type. These findings were published by Gay et al in Cancer Cell. SCLC is known for...
It All Began With a Lump in the Throat
BOOKMARK Title: Milkshakes and Morphine: A Memoir of Love and LifeAuthor: Genevieve FoxPublisher: VintagePublication date: January 2019Price: $15.95, paperback, 384 pages “It doesn’t hurt, but I know it is there and I know it shouldn’t be. Interloper. I have touched it a couple of times already,...
